SOHO 2022 | How novel agents may eliminate the need for transplant in ALL
Nicholas Short
• 29 Sep 2022
Nicholas Short, MD, University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the growing role of novel agents, including inotuzumab ozogamicin and ponatinib, in the treatment of acute lymphoblastic leukemia (ALL). Dr Short highlights how the use of these agents and chemotherapy-free regimens may eliminate the need for transplant in the future, and further discusses promising results that have been observed in clinical trials. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
